PHRENILIN FORTE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PHRENILIN FORTE (PHRENILIN FORTE).
Butalbital: barbiturate that enhances GABA-A receptor activity, causing CNS depression. Acetaminophen: analgesic and antipyretic via COX inhibition and central action. Caffeine: adenosine receptor antagonist, CNS stimulant.
| Metabolism | Butalbital: primarily hepatic via CYP2C19 and CYP2C9. Acetaminophen: hepatic via glucuronidation (UGT1A1, UGT1A9, UGT2B15), sulfation, and CYP2E1 (minor). Caffeine: hepatic via CYP1A2. |
| Excretion | Butalbital: ~60-70% renal as unchanged drug and metabolites. Acetaminophen: ~85% renal as sulfate and glucuronide conjugates (2-4% unchanged). Caffeine: ~1% renal unchanged; major metabolites are paraxanthine, theobromine, and theophylline eliminated renally. |
| Half-life | Butalbital: 35-50 hours (long-acting barbiturate). Acetaminophen: 2-3 hours (therapeutic doses); prolonged in overdose. Caffeine: 3-7 hours (average 5 hours); prolonged in liver disease. |
| Protein binding | Butalbital: ~30% bound to plasma proteins. Acetaminophen: <5% bound at therapeutic levels. Caffeine: ~35% bound to albumin. |
| Volume of Distribution | Butalbital: ~0.8 L/kg (widely distributed). Acetaminophen: ~1 L/kg. Caffeine: ~0.6 L/kg. |
| Bioavailability | Oral bioavailability: Butalbital 90% (well absorbed); Acetaminophen 85-95%; Caffeine 99% (essentially complete). |
| Onset of Action | Oral: 15-30 minutes for analgesic effect. Peak effects at 1-2 hours. |
| Duration of Action | Analgesic duration: 4-6 hours. Butalbital's sedative effects may persist longer due to long half-life. |
1 capsule (butalbital 50 mg, acetaminophen 325 mg, caffeine 40 mg) orally every 4 hours as needed; maximum 6 capsules per day.
| Dosage form | CAPSULE |
| Renal impairment | Not formally established. Acetaminophen component: avoid in severe renal impairment (CrCl <10 mL/min) due to accumulation of metabolites; adjust dosing interval to every 6 hours for CrCl 10-50 mL/min. |
| Liver impairment | Contraindicated in severe hepatic impairment (Child-Pugh class C). For mild to moderate impairment (Child-Pugh A or B): reduce dose to 1 capsule every 6 hours and monitor for hepatotoxicity. |
| Pediatric use | Not recommended for pediatric patients due to risk of butalbital dependence and acetaminophen hepatotoxicity. Alternative agents preferred. |
| Geriatric use | Initiate at 1 capsule every 6 hours; maximum 4 capsules daily. Renal and hepatic function should be monitored, and dose adjusted accordingly. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for PHRENILIN FORTE (PHRENILIN FORTE).
| Breastfeeding | Acetaminophen: minimal excretion, M/P ratio ~0.9, considered compatible. Butalbital: excreted in breast milk, M/P ratio ~0.6, may cause infant drowsiness or withdrawal; caution advised. Caffeine: M/P ratio ~0.5-0.8, generally safe in moderate amounts. |
| Teratogenic Risk | First trimester: Butalbital (barbiturate) associated with oral clefts, neural tube defects; acetaminophen generally safe, but high doses may cause oxidative stress. Second/third trimester: Butalbital may cause fetal dependence and withdrawal; acetaminophen safe at therapeutic doses. Avoid in pregnancy unless benefit outweighs risk. |
■ FDA Black Box Warning
Acetaminophen may cause severe hepatic injury, including acute liver failure, sometimes resulting in liver transplant or death. Butalbital is habit forming and may be abused; limit use to intermittent treatment.
| Serious Effects |
Hypersensitivity to any component; porphyria; severe hepatic impairment; concomitant MAO inhibitor use (or within 14 days)
| Precautions | Hepatotoxicity with acetaminophen overdose; avoid exceeding 4 g/day. Risk of dependence, abuse, and withdrawal with butalbital. CNS depression; avoid alcohol and other sedatives. Renal impairment, hepatic impairment. |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood pressure, hepatic function, and signs of barbiturate dependence. Fetal monitoring: assess growth, non-stress test, and biophysical profile if used chronically. Monitor neonate for withdrawal symptoms if used near term. |
| Fertility Effects | No known effects on fertility from acetaminophen or caffeine. Butalbital may induce hepatic enzymes affecting sex hormone metabolism, potentially altering menstrual cyclicity or ovulation; clinical significance unclear. |